Autolus Therapeutics’ (AUTL) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTLFree Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Separately, Truist Financial increased their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the company a buy rating in a report on Tuesday, April 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $8.70.

Get Our Latest Stock Analysis on Autolus Therapeutics

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $4.50 on Monday. Autolus Therapeutics has a one year low of $2.01 and a one year high of $7.45. The stock has a market cap of $1.20 billion, a PE ratio of -3.75 and a beta of 2.02. The stock has a 50 day moving average price of $4.58 and a 200 day moving average price of $5.37.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last posted its quarterly earnings results on Friday, May 17th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million during the quarter, compared to analysts’ expectations of $50.00 million. During the same period in the previous year, the company posted ($0.23) earnings per share. As a group, analysts predict that Autolus Therapeutics will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AUTL. Avoro Capital Advisors LLC purchased a new position in shares of Autolus Therapeutics during the first quarter worth $78,765,000. Price T Rowe Associates Inc. MD boosted its position in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth $11,793,000. Affinity Asset Advisors LLC boosted its position in shares of Autolus Therapeutics by 117.7% during the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock worth $21,532,000 after buying an additional 1,824,592 shares during the period. Finally, Lynx1 Capital Management LP purchased a new position in shares of Autolus Therapeutics during the third quarter worth $3,176,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Further Reading

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.